Nitrous Oxide Lawsuit Individuals who suffered harm, or families who lost a loved one after using nitrous oxide products may be eligible for financial compensation through a nitrous oxide lawsuit.
Hair Relaxer Lawsuit Regular exposure to chemicals in hair relaxer may cause uterine cancer, ovarian cancer and other injuries. Women diagnosed with cancer may be eligible for settlement benefits.
Depo-Provera Lawsuit Depo-Provera lawsuits are being investigated for women who developed meningioma brain tumors after receiving Depo-Provera birth control shots, claiming that Pfizer failed to adequately disclose side effects.
Ozempic Lawsuit Lawyers are pursuing Ozempic lawsuits, Wegovy lawsuits and Mounjaro lawsuits over gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects
Suboxone Tooth Decay Lawsuit Lawsuits are being pursued by users of Suboxone who experienced tooth loss, broken teeth or required dental extractions. Settlement benefits may be available.
Change Healthcare Lawsuit Lawyers are reviewing Change Healthcare class action lawsuits for individuals who had their personal information stolen due to the data breach.
AngioDynamics Port Catheter Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Bard PowerPort Lawsuit Serious and life-threatening injuries have been linked to problems with Bard PowerPort. Lawsuits are now being pursued by individuals who suffered injuries from the implantable port catheter fracturing or migrating.
Processed Food Lawsuit Lawsuits are being pursued against the food industry over their manufacturing and advertising of ultra-processed foods, which have caused a generation of children to face an increased risk of developing childhood diabetes and other chronic illnesses.
AFFF Lawsuit Exposure to firefighting foam chemicals may result in an increased risk of cancer for firefighters, military and airport personnel.
Pradaxa Lawsuits Raise Questions Over Clinical Trial Data Accuracy February 26, 2014 Irvin Jackson Add Your Comments A university and research center have found themselves brought into the Pradaxa litigation, with claims raised in some lawsuits alleging that inaccurate clinical trial data provided by the institutions helped the controversial blood thinner obtain approval in the U.S.  At least two Pradaxa lawsuits name McMaster University and Hamilton Health Sciences as co-defendants, along with the drug’s manufacturer, Boehringer Ingelheim. The Canadian institutions run the Population Health Research Institute (PHRI), which conducted the clinical trial for Pradaxa, known as RE-LY. According to a report by The Spectator, an Ontario paper, it is likely they will eventually be made co-defendants in thousands of product liability lawsuits filed by individuals throughout the United States who allege they suffered severe and sometimes fatal bleeding problems that were caused by side effects of Pradaxa. Learn More About Pradaxa Internal Bleeding Lawsuit Side effects of Pradaxa may increase risk of severe bleeding and death. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Learn More About Pradaxa Internal Bleeding Lawsuit Side effects of Pradaxa may increase risk of severe bleeding and death. Learn More SEE IF YOU QUALIFY FOR COMPENSATION Lawsuits allege that the findings of the researchers drew a picture of a drug that was far safer and more effective than warfarin, a blood thinner that had been the standard anticoagulation therapy for decades. However, even before the drug was approved, questions arose about the quality of the clinical trial data and whether the institute was more focused on providing accurate information or pleasing Boehringer Ingelheim. Following thousands of adverse event reports, hundreds of deaths, and a growing number of complaints filed by those who were seriously injured or lost family members to the drug, the researchers now face even more questions and more suspicions regarding the clinical trial data. Data Questioned Before Pradaxa Was Approved Pradadxa (dabigatran) is a relatively new anticoagulant therapy that was approved by the FDA in October 2010. It was the first member of a new class of medications known as direct thrombin inhibitors, which are promoted as superior alternatives to warfarin for stroke prevention because they require less monitoring during treatment. However, Pradaxa and other direct thrombin inhibitors lack an effective reversal agent to allow doctors to stop the blood thinning effects of the medication if a problems develops. Unlike warfarin, which can be quickly reversed with a dose of vitamin K and plasma, there is no available reversal agent for Pradaxa. While some studies have shown that the chances of bleeding may be about the same with the two drugs, evidence continues to emerge highlighting how Pradaxa bleeding problems may pose a more serious risk, since hemorrhages are typically harder to stop. Before Pradaxa (dabigatran) was approved, FDA reviewers already had concerns about the data PHRI had submitted. The reviewers found transposed numbers, missing adverse events data, and more. An investigation of the institute uncovered more deficiencies, including failings in data management plans and found a number of procedures and manuals necessary for the trial had never been created or were created months or years after patients were enrolled. “Although we recognized that there will be some errors in the data sets from large trials, the errors found by relatively unsophisticated means in clinically important data sets during preliminary review called into question the overall quality of those data sets and our confidence in them,” FDA reviewers wrote. The federal drug regulatory agency turned down Pradaxa until the data was resubmitted eight months later. Pradaxa Problems During the first full year the drug was on the market in the United States, the Institute for Safe Medication Practices (ISMP) found that adverse event reports involving Pradaxa problems surpassed all other medications regularly monitored by the group. The FDA received at least 3,781 reports involving serious injuries associated with the use of Pradaxa during 2011, including 2,367 reports of hemorrhage and 542 patient deaths. This further increased concerns about the problems with the RE-Ly trial. In a letter published in the Therapeutics Initiative in October 2011, researchers from the University of British Columbia warned that RE-LY was fundamentally flawed and said the drug should have never been approved. The researchers found that key parts of the study, which was supposed to be a double-blind trial, meaning neither doctors nor patients knew what they were taking, was actually not properly blinded, which resulted in differential treatment of patients in some cases. They also noted that there was a strangely elevated number of cases of warfarin brain bleeding incidents recorded. “Licensing of dabigatran 150 mg BID for atrial fibrillation is premature, pharmacologically irrational and unsafe for many patients,” they concluded. “An independent audit of RE-LY is needed to check for irregularities in conduct, sources of bias and the cause of the unusually high incidence of intracranial hemorrhage in the warfarin arm.” The institute has defended its numbers and officials from McMasters and HHS have expressed confidence in the institute’s procedures and integrity. Pradaxa Litigation Boehringer Ingelheim now faces about 2,000 lawsuits over Pradaxa that have been filed throughout the United States, alleging that the drug maker failed to adequately research the medication or warn consumers and the medical community about the potential bleeding risks, as well as the lack of an antidote to allow doctors to stop the blood thinning effects of the medication. Since August 2012, the federal Pradaxa litigation has been consolidated as part of an MDL, which is centralized before U.S. District Judge David R. Herndon in the Southern District of Illinois to reduce duplicative discovery, avoid conflicting rulings from different judges and to serve the convenience of the parties, witnesses and the courts. The company also faces Pradaxa lawsuits in state courts in Illinois, California and Connecticut. As part of the coordinated management of the cases in the federal court system, Judge Herndon has scheduled a series of early trial dates in the Pradaxa MDL, known as bellwether cases. These trials are set to begin between August 2014 and February 2015, with the outcomes designed to help the parties gauge how juries are likely respond to certain evidence and testimony that may be repeated throughout a large number of cases. Tags: Bleeding, Blood Thinner, Boehringer Ingelheim, Clinical Trials, Coumadin, Pradaxa, Warfarin More Pradaxa Lawsuit Stories Jury Awards $540K in Pradaxa Trial Against Boehringer Ingelheim May 21, 2019 Paragard IUD Lawsuit Dismissed on Summary Judgment February 25, 2019 Boehringer Ingelheim Ordered to Pay $1.25M For Failure to Warn About Pradaxa Bleeding Risks October 25, 2018 0 Comments Share Your CommentsFirst Name*Last NameEmail* Shared Comments*This field is hidden when viewing the formI authorize the above comments be posted on this page Yes No Post Comment I authorize the above comments be posted on this page Weekly Digest Opt-In Yes, send me a weekly email with the latest lawsuits, recalls and warnings. Want your comments reviewed by a lawyer?To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.Contact Phone #Alt Phone #Private CommentsNOTE: Providing information for review by an attorney does not form an attorney-client relationship.CAPTCHAGA SourceGA CampaignGA MediumGA ContentGA TermNameThis field is for validation purposes and should be left unchanged. Δ MORE TOP STORIES Ozempic Side Effects Caused Stomach Paralysis and Severe Abdominal Pain, Lawsuit Claims (Posted: yesterday) A product liability lawsuit filed against Novo Nordisk accuses the drug maker of failing to provide adequate warnings of Ozempic side effects, like stomach paralysis. MORE ABOUT: OZEMPIC LAWSUITOzempic Gastroparesis Lawsuit Filed Over Nausea, Severe Abdominal Pain (04/04/2025)Ozempic Delayed Gastric Emptying Led to Stomach Paralysis: Lawsuit (03/27/2025)Court Urged To Reject Motion To Dismiss Lawsuits Over Ozempic, Mounjaro Gastrointestinal Risks (03/21/2025) More Than 12,000 Hair Relaxer Cancer Lawsuits Filed Against L’Oreal, Other Cosmetics Companies (Posted: 2 days ago) Nearly a dozen different cosmetics companies face more than 12,000 hair relaxer lawsuits, involving claims that chemical straighteners caused women to develop uterine cancer, endometrial cancer, ovarian cancer and other injuries. MORE ABOUT: HAIR RELAXER LAWSUITUterine and Endometrial Cancer Caused by Hair Relaxer Products: Lawsuit (03/25/2025)Schedule for Hair Relaxer Lawsuit Bellwether Trials Outlined by MDL Judge (03/13/2025)Synthetic Braiding Hair Contains Cancer-Causing Chemicals: Consumer Reports (03/05/2025) Paraquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (Posted: 3 days ago) Lawyers involved in Paraquat Parkinson’s disease lawsuits pending in the federal court system indicate that they have reached an agreement to settle many of the claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSAppeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)Farmers Exposed to Certain Pesticides Face an Increased Risk of Rheumatoid Arthritis (12/11/2024)
Boehringer Ingelheim Ordered to Pay $1.25M For Failure to Warn About Pradaxa Bleeding Risks October 25, 2018
Ozempic Side Effects Caused Stomach Paralysis and Severe Abdominal Pain, Lawsuit Claims (Posted: yesterday) A product liability lawsuit filed against Novo Nordisk accuses the drug maker of failing to provide adequate warnings of Ozempic side effects, like stomach paralysis. MORE ABOUT: OZEMPIC LAWSUITOzempic Gastroparesis Lawsuit Filed Over Nausea, Severe Abdominal Pain (04/04/2025)Ozempic Delayed Gastric Emptying Led to Stomach Paralysis: Lawsuit (03/27/2025)Court Urged To Reject Motion To Dismiss Lawsuits Over Ozempic, Mounjaro Gastrointestinal Risks (03/21/2025)
More Than 12,000 Hair Relaxer Cancer Lawsuits Filed Against L’Oreal, Other Cosmetics Companies (Posted: 2 days ago) Nearly a dozen different cosmetics companies face more than 12,000 hair relaxer lawsuits, involving claims that chemical straighteners caused women to develop uterine cancer, endometrial cancer, ovarian cancer and other injuries. MORE ABOUT: HAIR RELAXER LAWSUITUterine and Endometrial Cancer Caused by Hair Relaxer Products: Lawsuit (03/25/2025)Schedule for Hair Relaxer Lawsuit Bellwether Trials Outlined by MDL Judge (03/13/2025)Synthetic Braiding Hair Contains Cancer-Causing Chemicals: Consumer Reports (03/05/2025)
Paraquat Settlement Reached for Parkinson’s Disease Lawsuits Filed in MDL (Posted: 3 days ago) Lawyers involved in Paraquat Parkinson’s disease lawsuits pending in the federal court system indicate that they have reached an agreement to settle many of the claims. MORE ABOUT: PARAQUAT PARKINSON’S DISEASE LAWSUITSAppeals Court Urged To Reinstate Paraquat Lawsuits Previously Set for Bellwether Trials (02/14/2025)Paraquat Lawsuits Over Parkinson’s Disease Risk Set for Trial in October 2025, April 2026 (01/29/2025)Farmers Exposed to Certain Pesticides Face an Increased Risk of Rheumatoid Arthritis (12/11/2024)